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BACKGROUND AND PURPOSE
Because biological systems behave as networks, multi-biomarker approaches increasingly replace single biomarker approaches in
drug development. To improve the mechanistic insights into CNS drug effects, a plasma neuroendocrine ﬁngerprint was iden-
tiﬁed using multi-biomarker pharmacokinetic/pharmacodynamic (PK/PD) modelling. Short- and long-term D2 receptor activa-
tion was evaluated using quinpirole as a paradigm compound.
EXPERIMENTAL APPROACH
Rats received 0, 0.17 or 0.86 mg·kg1 of the D2 agonist quinpirole i.v. Quinpirole concentrations in plasma and brain extracellular
ﬂuid (brainECF), as well as plasma concentrations of 13 hormones and neuropeptides, were measured. Experiments were
performed at day 1 and repeated after 7-day s.c. drug administration. PK/PD modelling was applied to identify the in vivo
concentration–effect relations and neuroendocrine dynamics.
KEY RESULTS
The quinpirole pharmacokinetics were adequately described by a two-compartment model with an unbound brainECF-to-plasma
concentration ratio of 5. The release of adenocorticotropic hormone (ACTH), growth hormone, prolactin and thyroid-stimulating
hormone (TSH) from the pituitary was inﬂuenced. Except for ACTH, D2 receptor expression levels on the pituitary hormone-
releasing cells predicted the concentration–effect relationship differences. Baseline levels (ACTH, prolactin, TSH), hormone release
(ACTH) and potency (TSH) changed with treatment duration.
CONCLUSIONS AND IMPLICATIONS
The integrated multi-biomarker PK/PD approach revealed a ﬁngerprint reﬂecting D2 receptor activation. This forms the concep-
tual basis for in vivo evaluation of on- and off-target CNS drug effects. The effect of treatment duration is highly relevant given the
long-term use of D2 agonists in clinical practice. Further development towards quantitative systems pharmacology models will
eventually facilitate mechanistic drug development.
Abbreviations
ACTH, adenocorticotropic hormone; BDNF, brain-derived neurotrophic factor; CRH, corticotrophin-releasing hormone;
FSH, follicle-stimulating hormone; GH, growth hormone; LH, luteinizing hormone; OFV, objective function value; PK/PD,
pharmacokinetic/pharmacodynamic; RSE, relative standard error; TIDA, tuberoinfundibular dopaminergic; TSH, thyroid-
stimulating hormone
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Introduction
Besides insufﬁcient information on drug distribution
into and within the brain, a main cause of attrition
in CNS drug development is the lack of translational
pharmacodynamic biomarkers, that is, preclinical bio-
markers that are predictive for clinical effect (Hurko
and Ryan, 2005; Soares, 2010; de Lange et al., 2017).
This enables the mechanistic extrapolation of drug effects
from animals to humans (Danhof et al., 2008; de Lange
et al., 2017).
It is important that these biomarkers are accessible in
humans. This poses a challenge for CNS drug develop-
ment, given that sampling from the human brain is
highly limited. However, the pituitary hormones and pep-
tides of the neuroendocrine system are released upon sig-
nals from the CNS, in particular the hypothalamus,
providing an opportunity to study central drug effects in
plasma. Dopamine, for example, is released from the
tuberoinfundibular dopaminergic (TIDA) neurons into the
median eminence of the pituitary to control the release
of prolactin from the lactotrophs into plasma (Freeman
et al., 2000). It has been shown that dopamine D2 ago-
nists stimulate the release of dopamine into the median
eminence (Eaton et al., 1993; Durham et al., 1997). This
principle has been used to evaluate the dopaminergic
drug efﬁcacy with prolactin (Movin-Osswald and
Hammarlund-Udenaes, 1995; Petty, 1999; Stevens et al.,
2012; Petersson et al., 2013; Taneja et al., 2016; van den
Brink et al., 2017), including the translation of these ef-
fects from rats to humans (Stevens et al., 2012; Petersson
et al., 2013).
Realizing that biological systems behave as networks,
single biomarker approaches are increasingly replaced by
multi-biomarker approaches (van der Greef and Mcburney,
2005; van der Greef et al., 2007). Although prolactin is a
sensitive biomarker for dopamine D2 receptor activation,
it is also sensitive to 5-HT and thyroid-releasing
hormone (TRH; Lyons and Broberger, 2014). A multi-
biomarker approach is envisioned to provide a more
speciﬁc reﬂection of D2 receptor activation. Indeed, the
dopaminergic system has multiple connections to the
neuroendocrine system, including the release of prolactin,
growth hormone (GH) and thyroid-stimulating
hormone (TSH) (Tuomisto and Mannisto, 1985;
Pivonello et al., 2007). With that, it is important to
identify the pharmacokinetic/pharmacodynamic (PK/PD)
parameters that can be scaled from animals to humans
(Danhof et al., 2008). Moreover, dopaminergic drug effects
may change with increasing duration of treatment follow-
ing sensitization and tolerance, as was shown for D2
agonists (Tirelli and Jodogne, 1993).
The aim of the current study was, therefore, to charac-
terize both the short-term and longer-term interactions of
the dopaminergic system with the neuroendocrine system,
in order to obtain a ﬁngerprint biomarker of D2 receptor
activation. The selective D2/3 agonist quinpirole will be
used as a paradigm compound. Here, we present a PK/PD
ﬁngerprint of quinpirole with adenocorticotropic hor-
mone (ACTH), GH, prolactin and TSH as neuroendocrine
biomarkers.
Methods
Animals, surgery and experiment
Animals. Animal studies are reported in compliance with
the ARRIVE guidelines (Kilkenny et al., 2010; McGrath &
Lilley, 2015) and were performed in agreement with the
Dutch Law of Animal Experimentation and approved by
the Animal Ethics Committee in Leiden, the Netherlands
(study protocol DEC12247). Male Wistar rats (n = 44) were
housed in groups for 6–9 days until surgery (Animal
Facilities Gorlaeus Laboratories, Leiden, the Netherlands).
Animals were held under standard environmental
conditions while artiﬁcial daylight was provided from
7:30 AM to 7:30 PM. They had ad libitum access to food
(Laboratory chow, Special Diets Services, Tecnilab BMI,
Someren, the Netherlands) and acidiﬁed water.
Surgery. The surgery was performed following previously
reported procedures (Westerhout et al., 2012). The rats
received 2% isoﬂurane anaesthesia while undergoing
surgery. After induction of the isoﬂurane, 0.09 mL
Buprecare® (AST Farma B.V., Oudewater, the Netherlands)
was administered i.m. Cannulas were placed in the
femoral artery for serial blood sampling and the femoral
vein for drug administration. Probe guides (CMA/12) with
dummy probes were implanted in caudate putamen in
both hemispheres (1.0 mm anterior, 3.0 mm lateral,
3.4 mm ventral, relative to bregma) and replaced by the
probes (CMA/12 Elite – 4 mm) 24 h before the
experiment. After the surgery, the animals received
0.15 mL Ampicillan® (Dechra Veterinary Products B.V.,
Bladel, the Netherlands) and 3 mL 0.9% NaCl s.c. The rats
were individually held in Makrolon type 3 cages for
7 days to recover and weighed on a daily basis to evaluate
the recovery.
Experiments. The rats were randomly assigned to receive 0
(n = 12), 0.17 mg·kg1 (n = 16) or 0.86 mg·kg1 (n = 16) i.v.
quinpirole between 10:45 AM and 11:15 AM on the ﬁrst
day of the experiment. The smaller group size for the
control group was chosen, because less variation was
expected in the data, that is, there is no inter-individual
variation from PK and the resultant PD processes. The
statistical non-linear mixed effect analysis (see Data
analysis section) is able to handle unbalanced study
designs. The microdialysate samples were collected from
200 to 180 min (20-min interval, 1.5 μL min1, 120 min
equilibration time) in polypropylene microvolume inserts
(250 μL; Waters, Etten-Leur, the Netherlands) containing
an antioxidant mix of 10 μL 0.02 M formic acid/0.04%
ascorbic acid in water. Blood samples of 200 μL were
collected in heparin-coated Eppendorf tubes at 5, 5, 7.5,
10, 15, 25, 45, 90, 120 and 180 min and centrifuged
(1000× g, 10 min, 4°C) to separate the plasma. All samples
were stored at 80°C until blinded analysis. After the
experiment, the cannulas were ﬁlled with a saline–heparin
solution (venous) or a PVP-heparin solution (arterial),
while a dummy replaced the probes. The rats received
their quinpirole dose s.c., until the second experiment on
day 8, which was executed as on day 1. After the
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experiment, the rats were killed following an overdose of
Nembutal®.
Chemical analysis of the samples
Quinpirole analysis in plasma and microdialysate. Quinpirole
(Bio-Connect, Huissen, the Netherlands) was analysed using
LC tandem MS (LCMS/MS). Calibration standards were
prepared in plasma with 0, 5, 10, 20, 50, 100, 200, 400 and
500 ng·mL1 and in buffered perfusion ﬂuid (bPF) with 0, 0.5,
1, 2, 5, 10, 20, 50, 100 and 200 ng·mL1 quinpirole. Quality
controls were prepared in plasma with 5, 10, 50 and
500 ng·mL1 and in bPF with 1, 6, 30 and 150 ng·mL1
quinpirole. Of the microdialysate samples, 20 μL was
transferred to microvolume inserts (BGB Analytik, Harderwijk,
the Netherlands) and spiked with 20 μL of 40 ng·mL1
internal standard ropinirole-D4 (Bio-Connect). Of the plasma
samples, 20 μL was spiked with 20 μL of the same internal
standard and 20 μL water before deproteination with 1 mL
acetonitrile (AcN). After centrifuging (20 000× g, 10 min), the
supernatant was transferred to an Eppendorf vial and dried by
CentriVap vacuum centrifugation (Labconco, Kansas City,
Missouri, USA). The residue was dissolved in 40 μL 5% AcN.
After being centrifuged (20 000× g, 10 min), the supernatant
was transferred to microvolume inserts and inserted into
1.5 mL screw cap vials.
The vials were placed into the Nexera X2 UHPLC–MS/MS
system (Shimadzu’s Hertogenbosch, the Netherlands) at
10°C; 5 μL of the sample was injected into the system, oper-
ated by LCQuan software (version 2.7, Thermo Fisher Scien-
tiﬁc, Breda, the Netherlands) and the MS Finnigan TSQ
quantum ultra-mass spectrometer (Thermo Fisher Scientiﬁc),
operated by XCalibur software (version 2.5, Thermo Fisher
Scientiﬁc). An Acquity UPLC BEH C18 column (130 Å,
1.7 μm, 2.1 mm × 50 mm; Waters) was used with a ﬂow rate
of 0.4 mL·min1 and a column temperature of 40°C. The mo-
bile phases were prepared in 10 mM ammonium acetate in
water (adjusted to pH 7 with formic acid). The aqueous mo-
bile phase (MPAQ) contained 5% and the organic mobile
phase (MPORG) 95% AcN. A gradient was applied with 10%
MPORG (0–0.5 min) to 100% MPORG (0.5–2.0 min) and kept
at 100% MPORG (2.0–2.8 min), after which the column was
re-equilibrated with 10%MPORG (2.8–3.0 min). The retention
time of quinpirole and ropinirole-D4 was 1.8 and 2.24min re-
spectively. The MS was used in positive electrospray ioniza-
tion mode, and all compounds were monitored by selective
reactionmonitoring. The ionization voltage, capillary energy,
capillary temperature and desolvation temperature were set
to 3.50 kV, 3 V, 150°C and 400°C respectively. The transition
ion pair was 220.18 m/z → 161.00 m/z, 16 V for quinpirole
and 265.22 m/z → 132.07 m/z, 32 V for ropinirole-D4. The
quality of the method was assured following the guidelines
for bioanalysis (Viswanathan et al., 2007). The unbound frac-
tion of quinpirole in plasma was determined to be 71 ± 3%
(concentration-independent) by ﬁltrating plasma samples
using high-speed ﬁltration (Centrifree®, Merck Millipore,
Amsterdam, the Netherlands; 2000× g, 10 min) and calcu-
lating the ratio of unbound to total plasma concentrations.
The total plasma concentrations of quinpirole measured
were corrected accordingly to obtain unbound plasma con-
centrations. The recovery of quinpirole over the microdial-
ysis probe was determined to be 5.4 ± 1.7% (n = 191) using
the retrodialysis method (de Lange, 2013). The
microdialysate quinpirole concentrations measured were
corrected for probe recovery to obtain the brainECF
concentrations.
Pituitary hormones and neuropeptides in plasma. The pituitary
hormones [ACTH, brain-derived neurotrophic factor
(BDNF), follicle-stimulating hormone (FSH), GH,
luteinizing hormone (LH), prolactin and TSH] and
neuropeptides (α-melanocyte-stimulating hormone,
β-endorphin, neurotensin, orexin A, oxytocin,
substance P) were analysed by multiplex assays
(RTPMAG-86K and RMNPMAG-83K, Merck Millipore,
Darmstadt, Germany) on a Bio-Plex® MAGPIX™ system
(BioRad Laboratories, Veenendaal, the Netherlands). With
the RTPMAG-86K, 10 μL and with the RMNPMAG-83K,
50 μL plasma was used for analysis according to the protocol
provided by the manufacturer.
Data analysis
The data and statistical analysis comply with the recommen-
dations on experimental design and analysis in pharmacol-
ogy (Curtis et al., 2018).
PK/PD modelling software and criteria. The PK/PD models to
describe the quinpirole and the hormone concentrations in
brainECF and plasma were developed by a two-stage
approach (the PK parameters were ﬁxed before developing
the PD models), using a non-linear mixed effect population
approach in NONMEM® version 7.3.0 with subroutine
ADVAN13. The inter-individual variability around the
parameters and the residual error was described by
an exponential distribution (Supporting Information
Equations S1 and S2). Model selection was based on
successful convergence, objective function value (OFV),
parameter precision and visual evaluation of the model
predictions as compared to the observations.
Pharmacokinetic model development. Two- and three-
compartment models were compared, with both linear or
non-linear clearance from plasma for their description of
unbound quinpirole concentrations in plasma and brainECF.
Here, it should be noted that a two-compartment model
refers to one compartment describing plasma and another
compartment describing brainECF quinpirole concentrations.
The transport into and out of the brain across the
blood–brain-barrier in these models was estimated with two
separate distribution clearances. The experiment day was
evaluated as covariate on one of the model parameters. The
model selected was evaluated on additional data to guarantee
external validity, and the details of which are described in the
Supporting Information Data S1.
Pharmacodynamic model development. For each hormone,
baseline, PK/PD and covariate models were developed in a
step-wise manner. Baseline patterns were evaluated on
placebo data following Supporting Information Equations
S4–S7, Part I. The selected baseline models were, together
with the pharmacokinetic model, integrated into the PK/PD
models. The PK/PD models were deﬁned as a combination
of the following characteristics: (i) baseline model for each
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hormone, (ii) plasma or brainECF as target site, (iii) the slope,
the EMAX, the alternative EMAX (Schoemaker et al., 1998), the
on–off or no drug effect model, and (iv) the direct response,
the turnover or the pool model as link model (Supporting
Information Equations S9–S16, Part I). The best model was
automatically selected on the basis of model convergence
and OFV. Finally, the PK/PD models selected were evaluated
for an effect of experiment day using step-wise covariate
model building (Khandelwal et al., 2011) (Supporting
Information Equations S17–S19, Part I).
Estimation of signal transduction efficiency. The quantitative
relation between receptor binding and pharmacological
effect depends on the signal transduction efﬁciency (Jonker
et al., 2005; Danhof et al., 2007), which is made explicit in
the operational model of agonism (Black and Leff, 1983).
Therefore, the PK/PD models selected were simulated and
ﬁtted by the operational model (Equation 1) (Black and Leff,
1983; Danhof et al., 2007):
E ¼ EmτC
kA þ 1þ τð ÞC : (1)
In which Em is the systems maximum, τ is the transduc-
tion efﬁciency and kA is the afﬁnity for the D2 receptor. It
was assumed that the target site of action is in the brainECF.
Furthermore, the assumption was made that quinpirole is se-
lective for the dopamine D2 receptor, and the GH, prolactin
and TSH responses were modulated via the TIDA neurons
(Figure 2). Therefore, the afﬁnity of quinpirole to the D2 re-
ceptor was estimated equal among all hormones, while the
signal transduction efﬁciency of GH, prolactin and TSH was
assumed dependent on pituitary D2 receptor expression ob-
tained from literature (Goldsmith et al., 1979). The D2
receptor expression for somatotrophs, lactotrophs and
thyrotrophs was calculated as the number of ‘troph’ cells ex-
pressing the D2 receptor relative to the total number of
‘troph’ cells. This relation to the signal transduction efﬁ-
ciency was made explicit following Equation 2:
τ ¼ τ0eslpreceptor expression; (2)
where τ is estimated for GH, prolactin and TSH on the basis of
the pituitary D2 receptor expression.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are
hyperlinked to corresponding entries in http://www.
guidetopharmacology.org, the common portal for data from
the IUPHAR/BPS Guide to PHARMACOLOGY (Harding et al.,
2018), and are permanently archived in the Concise Guide
to PHARMACOLOGY 2017/18 (Alexander et al., 2017).
Results
Pharmacokinetics of quinpirole in plasma and
brainECF
A two-compartment model best described the pharmacoki-
netics of quinpirole in plasma and brainECF with linear
ﬁrst-order elimination from plasma and a net active inﬂux
from plasma to brainECF (Supporting Information Equation
S3). The parameter estimates were precise and accurate
(Table 1), and the model could well describe the quinpirole
concentrations in plasma and brainECF over a large dose
range (Figure 1A). Although there is a slight over-prediction
of quinpirole concentrations in brainECF, external validation
showed good extrapolative ability of the model (Figure 1B).
Responding pituitary hormones and neuropeptides in
plasma. On the basis of automated model selection, the
hormones luteinizing hormone, prolactin and TSH showed
a placebo response described by circadian rhythm with a
Table 1
Parameter estimates of the quinpirole pharmacokinetic model
Parameter
Model evaluation Bootstrap (nbtstr = 168)
Estimate (RSE)[shr] Estimate (CV)
CLPL,o (L·h
1) 0.71 (9%) 0.70 (9%)
IIV CLPL,o 0.12 (32%) [7%] 0.12 (35%)
CLPL,ECF (L·h
1) 2.5 (20%) 2.5 (19%)
CLECF,PLASMA (L·h
1) 0.52 (24%) 0.55 (24%)
kp,uu (CLPL,ECF/CLECF,PL) 5 – – –
VCENTRAL (L) 1.0 (6%) 1.0 (7%)
VECF (L) 0.12 (13%) 0.013 (17%)
RUV CQP,PL 0.08 (24%) [3%] 0.08 (24%)
RUV CQP,ECF 0.12 (28%) [2%] 0.12 (30%)
C, concentration; CL, clearance; CV, coefﬁcient of variation; ECF, brain extracellular ﬂuid; IIV, inter-individual variability; kp,uu, ratio of unbound brainECF
and plasma drug concentration; nbtstr: number of successful bootstrap model runs out of a total of 200 runs; PL, plasma; RUV, residual unexplained
variability; shr, shrinkage; V, volume of distribution.
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period of 120 min, the Bateman equation or exponential
decay respectively (Supporting Information Figure S1A). A
model with no baseline pattern best described the other
hormone baselines. ACTH, GH, prolactin and TSH
responded to quinpirole treatment with diverse PK/PD
relations, while no effect was observed on the
neuropeptides, BDNF, FSH and LH, following automated
model selection (Supporting Information Figure S1B,
Table 2). Except for kdeg,ACTH [relative standard error
(RSE) = 282%] and EC50,Prl (RSE = 99%), the parameters were
identiﬁed with reasonable precision (Table 3), and the
models could describe the data well (Supporting
Information Equations, Part II; Figure S2).
Target site of effect. No statistically signiﬁcant difference was
identiﬁed comparing the best models for ACTH, GH,
prolactin and TSHwith either plasma or brainECF as target site
(Table 3).
Mechanistic evaluation of quinpirole effect on ACTH, GH,
prolactin and TSH. The concentration–effect relations
between quinpirole and every single hormone are depicted in
Figure 3, assuming brainECF as target site (Table 3).
Prolactin was most sensitive to quinpirole with a potency
of 0.93 ng·mL1, while ACTH, GH and TSH responded
with a potency of 54 ng·mL1, 101 ng·mL1 and
178 ng·mL1 respectively (Table 3). The operational
model could ﬁt the simulated concentration–effect
relationships well (Figure 3; Table 4). Within this model,
the signal transduction efﬁciency values (τ) of GH,
prolactin and TSH could be related to the pituitary
receptor expression on the somatotrophs, lactotrophs and
thyrotrophs respectively. In contrast, the ACTH
concentration–response relationship could not be ﬁtted
under the assumption of signal transduction efﬁciency
being dependent on pituitary D2 receptor expression
(Supporting Information Figure S3).
Figure 1
Visual predictive check (A) and external validation (B) for the quinpirole pharmacokinetic model in plasma and brainECF. The coloured dots rep-
resent the observed data, with the solid coloured lines showing the mean of the observations. The solid grey line shows the mean, and the dashed
grey lines show the 90% conﬁdence interval of 500 simulations. *The experiments in which the animals received 0.43 mg·kg1 and 2.14 mg·kg1
represented experimental protocol deviations (higher dose) and were included in PK model development only.
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One-day versus eight-day treatment responses. The
pharmacokinetics of quinpirole were not signiﬁcantly
inﬂuenced by 8-day drug treatment. In contrast, the
pharmacodynamics showed a signiﬁcant change for ACTH,
prolactin and TSH (Supporting Information Table S1). The
differences between the responses after short- and long-
term treatment are graphically presented in Figure 4. The
basal levels of ACTH were increased independent of dose,
while the hormone release rate was increased in a dose-
dependent manner. This resulted in a lower maximal ACTH
response after 8-day treatment with a high dose as
compared to a low dose of quinpirole. The basal prolactin
concentrations after 8 days were increased with dose, while
the extent of the placebo effect was decreased, independent
of dose. The basal levels of TSH have decreased with 8-day
treatment regardless the dose, while the sensitivity to
quinpirole (EC50) was decreased in a dose-dependent
manner.
Discussion
This study systematically evaluated the effects of quinpirole
on the neuroendocrine system following a PK/PD based
multi-biomarker approach. Quinpirole showed a high rate
of transport over the blood–brain-barrier with an unbound
partition coefﬁcient (kp,uu) of 5. ACTH, GH, prolactin and
TSH responded to quinpirole, each with a unique target site
Table 2
The PK/PD effects of quinpirole on ACTH, GH, prolactin and TSH, including the PK/PDmodel type and target site of drug action that was identiﬁed
Hormone Effect PK/PD model Target site
ACTH + Slope model and pool model with stimulation of kREL Plasma
GH  EMAX model and turnover model with inhibition of kREL BrainECF
Prolactin  EMAX model and turnover model with inhibition of kREL BrainECF
TSH  EMAX model and turnover model with inhibition of kREL BrainECF
ECF, extracellular ﬂuid; Effect: + increased release,  reduced release; kREL, hormone release rate.
Figure 2
The interaction between quinpirole and the neuroendocrine systemwith the pharmacokinetics as white compartments and the pharmacodynam-
ics as grey compartments. Quinpirole stimulates TIDA neurons in the hypothalamus to increase the release of dopamine into the pituitary. Dopa-
mine inhibits the release of GH, prolactin (PRL) and TSH into plasma. ACTH was stimulated by quinpirole, suggesting a pathway other than TIDA
neuron stimulation. The site of the main effect is assumed to be the brain, given the high quinpirole in brainECF as compared to plasma. QP,
quinpirole; DA, dopamine.
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concentration–effect relationship, providing a ﬁngerprint of
D2 receptor activation. Additionally, while no changes were
found in PK, the pharmacodynamics changed with 8-day
administration both dependent and independent of the
quinpirole dose. This study underlines the need for integra-
tive multi-biomarker evaluations of drug effects to compre-
hend the system-wide pharmacological proﬁle.
Can the target site of effect be determined?
Since the ultimate purpose is to identify peripheral bio-
markers of the central drug effect, an important question is
Table 3
Parameter estimates of the PK/PD models for quinpirole effect on
ACTH, GH, prolactin and TSH with plasma and brainECF as target site
Plasma BrainECF
Estimate (RSE) Estimate (RSE)
ACTH
OFV 31.3 32.9
Baseline (pg·mL1) 3.74 (17%) 3.71 (17%)
IIVBaseline 0.68 (71%) [0%] 0.68 (72%) [0%]
Slope ([ng·mL1]) 0.873 (43%) –
EMAX – 2.35 (11%)
EC50 (ng·mL
1) – 54.1 (40%)
KDEG (min
1) 0.0146 (24%) 308 (282%)
KREL (min
1) 0.00760 (29%) 0.00421 (31%)
RUV 0.27 (21%) [3%] 0.27 (21%) [3%]
GH
OFV 667.6 664.1
Baseline (pg·mL1) 1002 (n.a.) 992 (25%)
EMAX 1 (n.a.) 1 (39%)
S0 ([ng·mL
1]) 0.0545 (n.a.) 0.00985 (53%)
EC50 (ng·mL
1) 18.4 (calc.) 101 (calc.)
KDEG (min
1) 0.0228 (n.a.) 0.0282 (22%)
RUV 2.48 (13%) 2.45 (13%)
Prolactin
OFV 377.0 373.5
Baseline (pg·mL1) 284 (25%) 262 (25%)
IIVBaseline 0.70 (28%) [4%] 0.67 (28%) [4%]
DPlac (pg·mL
1) 8.72 (ﬁx) 8.72 (ﬁx)
KIN, Plac (min
1) 1.65 (ﬁx) 1.65 (ﬁx)
KDEC, Plac (min
1) 1.55 (ﬁx) 1.55 (ﬁx)
EMAX 0.961 (21%) 0.959 (13%)
EC50 (ng·mL
1) 0.0983 (275%) 0.933 (99%)
KDEG (min
1) 0.584 (22%) 0.0652 (22%)
RUV 0.79 (18%) [3%] 0.79 (18%) [3%]
TSH
OFV 272.2 270.0
Baseline (pg·mL1) 305 (5.3%) 293 (4.7%)
IIVBaseline 0.047 (30%) [8%] 0.045 (30%) [9%]
KDEC, Plac (min
1) 0.00489 (ﬁx) 0.00489 (ﬁx)
EMAX 0.819 (36%) 0.794 (32%)
EC50 (ng/mL) 31.2 (30%) 178 (34%)
KDEG (min
1) 0.0781 (13%) 0.126 (20%)
RUV 0.17 (19%) [2%] 0.18 (19%) [2%]
In bold the parameters of the selected models. DPlac, the extent of the
placebo effect; ECF, extracellular ﬂuid; EC50, concentration at half
maximal drug effect; EMAX, maximal drug effect; kDEC, dose-indepen-
dent hormone decay; kDEG, hormone elimination rate; kREL, hormone
release reate; RUV, residual unexplained variability; S0, EMAX/EC50.
Figure 3
(A) Simulated concentration–effect relationships for ACTH, TSH, GH
and prolactin (PRL) on the basis of the parameter estimates in Table-
3. The dark segments represent the quinpirole concentration range
measured in brainECF. The dotted lines represent the ﬁt with the op-
erational model, in which the signal transduction efﬁciency τ for GH,
prolactin and TSH is dependent on D2 receptor expression following
Equation 2.
Table 4
Relative D2 receptor expression on the troph cells in the rat anterior
pituitary, the signal transduction efﬁciency τ and the systems maxi-
mal effect Em estimated from the operational model in Equation 1
D2 receptor expression
(Goldsmith et al., 1979) τ EM
Corticotrophs
(ACTH)
20% 13.8 2.51
Somatotrophs
(GH)
34% 8.7 1.11
Lactotrophs
(prolactin)
76% 743 0.96
Thyrotrophs
(TSH)
13% 0.94 1.76
The kA was estimated 805 ng·mL
1 (see Equation 1), while the τGH,
τprolactin, τTSH was described by τ = 0.24*e
0106*receptor expression.
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whether we can consider brainECF concentrations as the tar-
get site concentrations of the effect of quinpirole. We have
shown that, on the basis of statistical signiﬁcance, it was
not possible to discriminate between brainECF and plasma as
target site of effect. Given that the D2 receptors on the ‘troph’
cells are accessible from plasma and the release of these hor-
mones have been modiﬁed by systemic dopamine infusion
(Besses et al., 1975; Vance et al., 1987), it is suggested that
these hormones are released upon peripheral drug action.
On the other hand, the release of these hormones is tightly
controlled by signals from the hypothalamus that are highly
connected to dopamine and other neurotransmitter systems.
Considering this, the rate and extent of drug distribution into
the brain may determine the dominant target site of effect.
For the D2 antagonist remoxipride (kp,uu = 1) (van den Brink
et al., 2017), brainECF could be considered as target site to re-
lease prolactin into plasma, while for the D2 antagonist ris-
peridone (kp,uu = 0.45) (Yamamoto et al., 2016), plasma
could be considered as target site (Stevens et al., 2012;
Shimizu et al., 2017; van den Brink et al., 2017). Quinpirole
is found to be subjected to active inﬂux: although no infor-
mation on the transporter is available in literature, it is ob-
served that, under steady state conditions, the free drug
concentration in brainECF is as much as ﬁve times higher than
in plasma (kp,uu = 5; Table 1). Therefore, although we could
not provide a statistical determination, it is presumed that
the main effect of quinpirole on the neuroendocrine system
is mediated via the brain rather than via the periphery.
Interpretation of the unique
concentration–effect relationships
Dopamine activity in the brain is reﬂected in the
tuberoinfundibular dopamine pathway that consists of three
types of neurons that project from the hypothalamus to the
pituitary: (i) the TIDA neurons, (ii) the periventricular hypo-
physeal dopamine neurons and (iii) the tuberohypophyseal
dopamine neurons (Freeman et al., 2000). TIDA neurons re-
lease dopamine into the long portal veins of the pituitary to
which the ‘troph’ cells are exposed. While quinpirole has af-
ﬁnity for both the D2 and the D3 receptor (Millan et al.,
2002), the effects on the neuroendocrine system are puta-
tively mediated via the D2 receptor because of the following
ﬁndings. First, the enhancing effect of quinpirole on ACTH
release was reversed with administration of the D2 receptor
antagonist sulpiride (Borowsky and Kuhn, 1992; Kurashima
et al., 1996). Second, the effect of quinelorane, which is simi-
larly speciﬁc for the D2/3 receptor, on the neuroendocrine
TIDA neurons was antagonized by the selective D2 receptor
antagonist raclopride (Eaton et al., 1993). Third, while the se-
lective D2 agonist PNU-95666 activated the TIDA neurons
and inhibited prolactin release, this was not the case for the
selective D3 agonist PD128907 (Durham et al., 1997). In con-
trast, studies with selective D2 and D3 agonists in ovariecto-
mized oestrogen-primed female rats showed a decrease of
TIDA neuron activity and an increase of subsequent prolactin
release (Liang and Pan, 2012; Liang et al., 2014). However, the
oestrogen-priming in these studies prevents a direct compar-
ison between these results and our results, since oestrogen in-
terferes with TIDA neuron activity as well as the sensitivity of
the pituitary to dopamine (Gudelsky et al., 1981; Morel et al.,
2009). Indeed, our study design is more similar to that of the
studies observing activation of TIDA neuron activity and sup-
pression of prolactin release, that is, they studied male rats or
diestrous female rats with low oestrogen levels (Eaton et al.,
1993; Durham et al., 1997). Therefore, we assume that the
stimulation of TIDA neuron activity by of quinpirole in our
Figure 4
Simulated hormone actual (A) and baseline normalized (B) concentration-time proﬁles of ACTH, prolactin (PRL) and TSH after one administration
(solid black line) and eight administrations (dashed grey line).
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study is D2 speciﬁc. Dopamine D2 receptors were identiﬁed
not only on lactotrophs (prolactin) but also on corticotrophs
(ACTH), somatotrophs (GH), gonadotrophs (FSH, LH) and
thyrotrophs (TSH) (Goldsmith et al., 1979; Pivonello et al.,
2007). Also, dopamine agonists inhibited the release of
ACTH, GH, prolactin and TSH in vitro, likely mediated via
the D2 receptors (Ishibashi and Yamaji, 1984, 1981; Foord
et al., 1986). Overall, it is thus expected that ACTH, GH, pro-
lactin and TSH concentrations decrease with quinpirole treat-
ment upon the stimulation of TIDA neuron activity that
enhances dopamine release into the pituitary to bind to the
pituitary dopamine receptors on the ‘troph’ cells. Interest-
ingly, the secretion of ACTH was increased, indicating a dif-
ferent mechanism of action not via the TIDA neurons. The
hypothalamic mediator of ACTH release is corticotrophin-
releasing hormone (CRH). CRH is under control of several
neurotransmitters, for example, noradrenaline and γ-
aminobutyric acid. Since the effect of quinpirole on ACTH
was found to be D2 receptor speciﬁc (Borowsky and Kuhn,
1992), it is likely that CRH or the controlling neurotransmit-
ters are inﬂuenced in a D2 speciﬁc manner (Figure 2).
According to these mechanisms, the assumptions of D2
receptor selectivity for all hormones and the pituitary D2 re-
ceptor expression dependent signal transduction for GH, pro-
lactin and TSH were made (Figure 2; Table 4). Conceptually,
the differences in signal transduction efﬁciency may also be
explained by differences in fractional receptor occupancy
needed to elicit a certain level of pituitary hormone release,
that is, the release of some hormones may be more sensitive
to dopamine receptor activation than to that of other hor-
mones. However, our assumptions are conﬁrmed by a good
ﬁt of the operational model on the simulated concentration
effect relationships as depicted in Figure 3. Physiologically,
this suggests a receptor expression dependent sensitivity of
the hormones to the increase of pituitary dopamine follow-
ing the central quinpirole effect. In fact, it indicates that τ in-
deed is a system-speciﬁc parameter. The opposed direction of
the ACTH response and the deviation of τACTH from the rela-
tion between receptor expression and τ indicate a different
mechanism of action of D2 receptor activation on ACTH re-
lease (Figure 3; Table 4; Supporting Information Figure S3).
Altogether, the systems response expressed in terms of signal
transduction efﬁciency provides a ﬁngerprint that is speciﬁc
for D2 receptor stimulation in the brain.
Habituation, tolerance and homeostatic
feedback mechanisms
There are three mechanisms through which the differences
between day 1 and day 8 are explained (Figure 4). First of
all, the dose-independent changes are likely the consequence
of habituation; the animals’ response to the daily injection
procedure returns to basal levels with longer term administra-
tion. Indeed, the ACTH and TSH basal levels and the prolactin
placebo response changed over the period of quinpirole ad-
ministration (Figure 4). Second of all, pharmacodynamic tol-
erance may occur as a consequence of long-term drug
administration (Dumas and Pollack, 2008). Tolerance is the
mechanism of physiological adaptation to continuous exter-
nal stimuli, for example, the change in receptor expression.
Pharmacodynamic tolerance was identiﬁed for the TSH
response, as indicated by the dose-dependent change of
EC50 (Figure 4, Supporting Information Table S1). Assuming
a D2-dependent mechanism, this cannot be explained by re-
duced hypothalamic D2 receptor expression, since this was
not observed for the other hormones. Moreover, D2 receptor
expression was found not to change with long-term D2 ago-
nist exposure (Cho et al., 2010). Possibly, the balance between
other mediators of TSH release and dopamine has changed,
thereby inﬂuencing the transduction efﬁciency. Third of all,
the differences between the experiment days can be
explained by homeostatic feedback mechanisms. The release
rates of ACTH and prolactin were increased in a dose-
dependent manner, suggesting a positive and negative
feedback respectively (Figure 4; Supporting Information
Table S1). These hormones are components of highly
complex networks that include multiple negative and
positive feedback mechanisms that are affected by 8-day
administration of quinpirole. The net effect is reﬂected in
the current analysis, showing that these networks have
changed to another equilibrium.
Strengths, limitations and future research
Our integrated PK/PD approach included multiple hor-
mones and neuropeptides that provide comprehensive in-
sight into the interaction between quinpirole and the
neuroendocrine system to reveal a ﬁngerprint reﬂecting
D2 receptor activation. Nevertheless, it has a few limita-
tions that will be discussed in this section. First of all, the
3-h duration of the experiments limited the evaluation of
the full pharmacodynamic response. While ACTH levels
were back to baseline at the end of the experiment, GH,
prolactin and TSH levels were still decreased. This may
have limited the precise identiﬁcation of the PK/PD model,
although, in general, the parameter estimates showed good
precision. Second, while for ACTH, prolactin and TSH the
baseline pattern could be well described; this appeared
more difﬁcult for GH. Visual evaluation of the baseline
GH pattern indicates that there might be temporal varia-
tion. However, no statistically signiﬁcant or robust model
could be identiﬁed describing such pattern. High random
variation in the data may have prevented such identiﬁca-
tion. Larger sample sizes than used in the current study
are advised to include the possible temporal variation of
GH. Third, a wider dose range may have enabled better
identiﬁcation of the EC50 parameter in case of, for exam-
ple, ACTH that was best described by a slope model. How-
ever, since a relatively untargeted approach was applied, it
was not possible to anticipate the dose range beforehand.
Moreover, the current choice of doses was based on an ex-
perimental regimen, reﬂecting the therapeutic range (Gao
et al., 1998; Adachi et al., 2003), in order to gain pharmaco-
logically relevant insights. Fourth, the choice of hormones
and neuropeptides, although guided by pharmacological
knowledge, was based on the available platforms rather
than based on the physiology. While this provides a non-
biased evaluation of neuroendocrine effects of quinpirole,
there is a series of hormones that will be of interest for fur-
ther research, for example, the downstream signals of the
pituitary hormones, such as will be discussed below.
Suggestions for further investigation include the valida-
tion of the D2 receptor activation ﬁngerprint with other
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selective D2 agonists, for example, quinelorane and
ropinirole (Millan et al., 2002). Furthermore, we suggest ef-
forts towards unravelling the mechanisms underlying the
quinpirole–hormone relationships that were identiﬁed in
the current study. Such investigation should include (i)
the measurement of quinpirole and dopamine in the hypo-
thalamus using microdialysis (Li and Yan, 2010); (ii) the
measurement of quinpirole and CRH, GHRH, dopamine
and TRH in the pituitary using microdialysis (Granveau-
Renouf et al., 2000); (iii) the measurement of ACTH, GH,
prolactin and TSH in plasma; (iv) themeasurement of cortico-
sterone, IGF-1, triiodithyronine, thyroxine as downstream
signals of ACTH, GH and TSH respectively; and (v) a study
duration of at least 6 h of experiment. This takes into account
the duration of quinpirole exposure (~4 h) as well as the delay
of the hormone responses.
Such data will form the basis of a quantitative systems
pharmacology model describing the interaction between
quinpirole and neuroendocrine system in terms of purely
drug- and system-speciﬁc parameters. This will also allow
the separation of central and peripheral quinpirole effect
since the drug concentration will be evaluated in both the
hypothalamus and the pituitary. Moreover, the upstream
hormones that are released from the hypothalamus will ex-
clusively reﬂect the hypothalamic interaction with the drug.
Eventually, such model can be evaluated with different
lengths of chronic administration periods to mechanisti-
cally understand the tolerance and homeostatic feedback
mechanisms.
Conclusion
The current study has made the case for an integrated and
system-wide approach to understand the interaction be-
tween dopaminergic pharmacology and the neuroendo-
crine system. It was shown that, under standard
experimental conditions, quinpirole interferes with the
hypothalamus–pituitary–adrenal axis (ACTH), the growth
hormone system (GH), parts of the reproductive system
(prolactin) and the thyroid function (TSH). With this
multi-biomarker approach, a ﬁngerprint of transduction ef-
ﬁciency values was obtained that is speciﬁc for D2 receptor
activation. In contrast to prolactin alone, as a classical bio-
marker, this multi-biomarker ﬁngerprint provides a speciﬁc
reﬂection of D2 receptor activation. Our study also indi-
cated a clear change of the PK/PD relationship with com-
paring short-term and long-term administration. This is
highly relevant, considering the long-term use of D2 recep-
tor agonists in clinical practice. Further understanding of
the underlying tolerance and homeostatic feedback mecha-
nisms will increase the proper application of these drugs in
clinical practice.
In conclusion, this study provided further insights into
the interaction between dopaminergic pharmacology and
the neuroendocrine system. Using a multi-biomarker ap-
proach, a ﬁngerprint of D2 receptor activation was obtained.
This forms the conceptual basis for the in vivo evaluation of
the on- and off-target effects of drugs in the CNS. Further ef-
forts towards quantitative systems pharmacology model de-
velopment will eventually lead to mechanistic translational
dopaminergic drug development.
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Figure S1 (A) Visualization of the automated model selec-
tions for the baseline model (A) and the PK/PD model (B) on
basis of adjusted objective function value (suppl. Equations
part I, 8). Grey dots represent the adjusted objective function
value for each evaluated model, while blue dots represent the
selected models.
Figure S2 Visual predictive check of the quinpirole PK/PD
models for ACTH, GH, prolactin (PRH) and TSH at experi-
ment day 1 and 8. The colored dots represent the observed
data, with the solid colored lines showing themean of the ob-
servations. The solid grey line shows the mean, and the
dashed grey lines the 90% conﬁdence interval of 500
simulations.
Figure S3 A) Simulated concentration-effect relations for
ACTH (black), TSH (green), GH (red) and prolactin (PRH;
blue) on basis of the parameter estimates in table III as com-
pared to the ﬁts by the operational model (equation 1). Each
ﬁgure represents a different scenario with regard to the hor-
mones included in the relation between tau and D2 receptor
expression (equation 2). The signal transduction efﬁciency τ
is assumed dependent on pituitary D2 receptor expression
for the hormones indicated above each ﬁgure. For the hor-
mone not included, the signal transduction efﬁciency τ is es-
timated separately.
Table S1 Parameter estimates for ACTH, prolactin (PRH) and
TSH with and without covariate effect.
Data S1 Supplementary Methods.
Data S2 Supplementary Equations.
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